Skip to content

Study · Animal study (in vivo) · rat · 1997

7 results

Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function.

Torsello A, Luoni M, Grilli R, Guidi M, Wehrenberg WB, Deghenghi R, Müller EE, Locatelli V

Neuroendocrinology1 Feb 1997Cited by 7 (Europe PMC)

PMID9067986 (opens in a new tab)DOI10.1159/000127168 (opens in a new tab)PepBankPUB-09067986
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In infant rats, hexarelin treatment for 3, 5 or 10 days progressively enhanced the plasma GH rise to a later acute hexarelin challenge.

    In plain wordsIn young rat pups, repeated hexarelin treatment increased the growth hormone rise to a later hexarelin dose.

    Peptide
    Hexarelin
    Outcome
    IncreasePlasma GH response to acute hexarelin challenge, infant rats
    Study

    ratn: not reported in source

    infant rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 3, 5 or 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin (80 micrograms/kg, b.i.d. s.c.), administered for 3, 5 or 10 days to 8-, 6- and 1-day-old rats, respectively, induced a progressive enhancement of the plasma GH rise elicited by a subsequent acute Hexarelin (80 micrograms/kg s.c) challenge when pups were 10 days old.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH antiserum-treated rat pups, hexarelin for 3-10 days significantly enhanced the GH response to acute hexarelin, but mean GH values stayed lower than in controls.

    In plain wordsIn rat pups with blocked GHRH, hexarelin raised the growth hormone response, though levels stayed below those of control pups.

    Peptide
    Hexarelin
    Outcome
    IncreasePlasma GH response to hexarelin, GHRH-antiserum-treated pups
    Study

    ratn: not reported in source

    infant rats given GHRH antiserum
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 3-10 daysAs given in this study (rat).

    Source sentences

    Summary
    In GHRH-Ab-treated pups, Hexarelin administration for 3-10 days significantly enhanced the GH response to the acute Hexarelin injection, though the mean plasma GH values remained significantly lower than in the respective control group.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In control infant rats, hexarelin treatment did not alter GH mRNA levels.

    In plain wordsIn normal rat pups, hexarelin did not change growth hormone mRNA levels.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH mRNA in control infant rats
    Study

    ratn: not reported in source

    infant rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 3, 5 or 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin treatment did not alter GH mRNA levels in control pups.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In GHRH antiserum-treated rat pups, hexarelin for 3 and 5 days, but not 10 days, restored GH mRNA levels to control values.

    In plain wordsIn rat pups with blocked GHRH, hexarelin for 3 and 5 days, but not 10 days, restored growth hormone mRNA to normal.

    Peptide
    Hexarelin
    Outcome
    MixedGH mRNA in GHRH-antiserum-treated pups
    Study

    ratn: not reported in source

    infant rats given GHRH antiserum
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 3, 5 or 10 daysAs given in this study (rat).

    Source sentences

    Summary
    In GHRH-Ab-treated pups Hexarelin treatment for 3 and 5 days, but not 10 days, restored GH mRNA levels to control values.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In young-adult male rats, regardless of antiserum treatment, hexarelin for 5 or 10 days significantly suppressed the GH response to a later acute hexarelin challenge.

    In plain wordsIn young adult rats, repeated hexarelin treatment lowered the growth hormone response to a later hexarelin dose.

    Peptide
    Hexarelin
    Outcome
    DecreasePlasma GH response to acute hexarelin challenge, young-adult rats
    Study

    ratn: not reported in source

    young-adult male rats, with or without GHRH antiserum
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 5 or 10 daysAs given in this study (rat).

    Source sentences

    Summary
    In young-adult male rats, regardless of antiserum treatment, Hexarelin administration for 5 or 10 days significantly suppressed the GH response to a subsequent acute challenge with the peptide.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In control young-adult rats, 5-10 days of hexarelin treatment did not alter GH mRNA.

    In plain wordsIn normal young adult rats, hexarelin did not change growth hormone mRNA.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH mRNA in control young-adult rats
    Study

    ratn: not reported in source

    young-adult male rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 5-10 daysAs given in this study (rat).

    Source sentences

    Summary
    Yet, 5-10 days of Hexarelin treatment did not alter GH mRNA in control young-adult rats.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In adult rats given GHRH antiserum, 10 days of hexarelin treatment were necessary to return GH mRNA to normal levels.

    In plain wordsIn adult rats with blocked GHRH, ten days of hexarelin were needed to bring growth hormone mRNA back to normal.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH mRNA in GHRH-antiserum-treated adult rats
    Study

    ratn: not reported in source

    adult rats given GHRH antiserum
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 micrograms/kg twice daily · subcutaneous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    In adult rats GHRH-Ab also decreased GH mRNA levels, but 10 days of Hexarelin treatment were necessary to return GH mRNA back to normal levels.
    1 context sentence
    Summary · context
    In the present study, we sought to characterize the effects of short-term Hexarelin treatment on GH release and GH mRNA levels in infant and young-adult rats and in rats of either age passively immunized with an antiserum against GHRH (GHRH-Ab).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.